Wednesday, July 23, 2014

FDA Warns Compounding Pharmacy Trio With cGMP Violations

 

FDA Warns Compounding Pharmacy Trio With cGMP Violations

A A
The FDA cited a trio of compounders for a wide swath of quality violations, igniting renewed criticism that the agency is “unjustified” in using a new law to enforce old violations.

To View This Article:

Login

Subscribe To Drug Industry Daily

No comments: